Navigation Links
Equashield's Sales Grow by 60% in 2013
Date:1/14/2014

PORT WASHINGTON, New York, January 14, 2014 /PRNewswire/ --

Equashield (http://www.equashield.com), the leading provider of Closed System Transfer Devices (CSTD) for hazardous drugs, today announced that it has achieved 60% year-over-year sales growth for the fourth straight year.  

Equashield's closed systems reduce the risk of exposure for pharmacy technicians, pharmacists, nurses and other medical professionals who prepare and administer hazardous drugs, such as chemotherapy. In addition, the solution helps to prevent microbial ingress, decreasing the risk of infection in patients receiving these drugs.

"Approximately 20% of hospitals and medical centers are already investing in closed systems to ensure their employees' safety," said Marino Kriheli, Product Manager at Equashield. "With growing awareness of the many risks associated with hazardous drug exposure, this market is rapidly growing. In fact, 55% of new customers Equashield acquired this year did not use closed systems previously. Furthermore, with the recent launch of Equashield II, the company's second generation CSTD, we expect major sales growth to continue in 2014 and beyond."

Equashield is the only preassembled closed syringe that requires no further setup, making it quicker and easier to use than other system on the market. Equashield devices are currently used in the Cleveland Clinic, Mt. Sinai Hospital in New York and hundreds of other medical facilities.

Equashield II covers more routes of exposure to hazardous drugs than alternative systems and is the only system that prevents contamination of syringe plungers by hazardous drugs.

"Contamination on syringe plungers has been clearly identified in recent studies, added Kriheli. "The quantities of drug residue found on plungers place this route of exposure among the top risks associated with handling hazardous drugs."

About Equashield

Equashield is a leading developer of closed system drug transfer devices that protect healthcare professionals from hazardous drug and vapor exposure. EQUASHIELD® provides superior safety & ease-of-use by covering more routes of exposure than alternative systems and by enabling faster use than other systems. EQUASHIELD® is clinically proven to eliminate surface contamination with antineoplastic agents and prevent microbial ingress, having demonstrated the ability to extend beyond-use dating for single-use or non-preserved drugs. The system consists of a unique syringe with encapsulated barrel and plunger, built-in closed pressure equalization, and an integrated single motion connector that remains free of drug residue even after multiple connections. EQUASHIELD® is the only preassembled CSTD syringe on the market that requires no further setup, thereby contributing to ease of use and overall hospital productivity. For more information, visit http://www.equashield.com.

Media Contact:
Finn Partners for Equashield
Ellie Hanson
ellie@finnpartners.co.il
+972-54-467-6980


'/>"/>
SOURCE Equashield
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardica Appoints Industry Veteran Liam Burns As Vice President, Sales And Marketing
2. AMRI Hires George Svokos as Senior Vice President Sales and General Manager - API
3. FPR Specialty Pharmacy Hires Slomski To Lead Sales And Marketing; Moves To Next Phase In Cleveland Clinic Trials
4. Simbionix Welcomes New Latin and Central American Sales Manager
5. Immunotherapies Will Continue to Dominate the Malignant Melanoma Drug Market with Sales of Immune Checkpoint Inhibitors Accounting for Majority of Sales in this Drug Class in 2022
6. TRU-D SmartUVC Sales Soar in 2013 with Increased Acceptance of Proven Infection Prevention Technology
7. Indegene Named a Leader in IDC MarketScape: Worldwide Life Science Sales and Marketing BPO 2013 Vendor Assessment
8. Vermillion Appoints Marian E. Sacco as SVP of Sales and Marketing and Chief Commercial Officer
9. The Chronic Pain Drug Market Will Attain $21.6 Billion in Major-Market Sales by 2022
10. Osseon Announces New Regional Sales Director
11. Cantel Medical Reports 19% Sales Growth And EPS Of $0.27 vs. $0.23 For The First Quarter Ended October 31, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
(Date:6/24/2016)... CHAPEL HILL, N.C. , June 24, 2016 ... in healthcare decisions and regulators/payers have placed more ... this new environment, patient support programs in the ... support for patients, medications. Consequently, pharmaceutical companies are ... to ensure they are providing products and services ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, affiliated ... Weintraub as a prominent plastic surgeon and the network’s newest partner. , ... most handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands ...
Breaking Medicine News(10 mins):